---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-004800"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2024-07-12T23:59:59+00:00"
generated_at: "2026-05-31T21:08:32.708122+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals raises $3.1M via warrant exercise at $5.45/share; issues new warrants

## Summary
- Gross proceeds ~$3.1M from cash exercise of 545,286 existing warrants at reduced price of $5.45/share (original range $324-$9.72).
- Holders pay additional $0.125 per new warrant for aggregate $136,321; total gross proceeds include this amount.
- New Series C (583,098 shares, 5.5-yr term) and Series D (507,474 shares, 18-mo term) warrants issued, exercise price $5.45.
- H.C. Wainwright acts as exclusive placement agent; receives 7.5% cash fee, $35k non-accountable expenses, and 40,896 warrants.
- Net proceeds to be used for working capital and general corporate purposes; offering closed July 12, 2024.

## SEC filing metadata
- accession: 0001683168-24-004800
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2024-07-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316824004800/0001683168-24-004800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316824004800/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-004800
- JSON: https://secwatch.observer/filing/0001683168-24-004800.json
- Plain text: https://secwatch.observer/filing/0001683168-24-004800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.